TG Therapeutics said it is working to develop a subcutaneous (under-the-skin) version of relapsing MS therapy Briumvi.

Researchers have shown that the amount of a protein called CD74 can indicate which people with bowel cancer may respond best to immunotherapy.

Scientists have made 'exciting,' patient-friendly advances in developing a non-toxic bacterial therapy, BacID, to deliver cancer-fighting drugs directly into tumors. This emerging technology holds ...

A completely new way of treating type 1 diabetes is being tested at Uppsala University Hospital. Patients are being offered ...

In a trial featuring a mouse model of Alzheimer's, scientists found that inhaling a mixture containing xenon gas helped ...

Nektar Therapeutics has completed target enrollment for its phase 2b study of rezpegaldesleukin for the treatment of patients ...

It’s a sobering statistic: 1 in 8 women in the United States will be diagnosed with breast cancer during her lifetime.1 ...

A stem cell clinic the FDA found to be operating illegally plans to appeal the agency's authority to the Supreme Court. The ...

A recent study has made significant strides in uncovering how the oral microbiome, particularly the bacterium Fusobacterium ...

Scientists have disguised tumours to ‘look’ similar to pig organs ― tricking the immune system into attacking the cancerous ...

Dr. Christopher R. Flowers delved into the meaning of MRD, discussing different ways that it may be tested for in patients ...

A University of Massachusetts Amherst-Ernest Pharmaceuticals team of scientists has made "exciting," patient-friendly advances in developing a non-toxic bacterial therapy, BacID, to deliver ...